Transorbital Therapy Guidance
Recently the National Eye Institute has categorized glaucoma as a disorder of the optic nerve (neuropathy) leading to new thinking about best treatments. The difficulty is the delivery of neuroprotective drugs to the optic nerve. Systemic delivery exposes all nerves to potential interaction with the drug and topical eye drops have been show to only deliver 5% of their concentration to the back of the eye. Neuroprotective drugs may require ongoing treatment and intravital injections lead to patient resistance. We have developed a novel drug delivery system with and innovative methodology for time release that allow specific delivery of the drug to the optic nerve and stretch the time between treatments.